O-304 (ATX-304) 100mg x60 Capsules
Pan-AMPK Activator for Diabetes, Fat Loss, and Heart Research
O-304 (ATX-304) is a first-in-class pan-AMPK activator showing remarkable results in Phase 2 trials for T2D — reducing HbA1c, body weight, and heart failure markers simultaneously. It activates all AMPK subunit complexes across tissues.
Pan-AMPK Activator for Diabetes, Fat Loss, and Heart Research
O-304 directly activates AMPK in muscle, liver, heart, and adipose tissue via allosteric activation of the β1 subunit, producing metabolic benefits across multiple systems simultaneously in clinical trials.
As one of the most studied compounds in the metabolic & fat loss research space, O-304 has attracted sustained scientific interest across AMPK biology research, Diabetes and metabolic research, Heart failure research. Peer-reviewed evidence indicates that phase 2 T2D: reduces HbA1c, body weight, and NT-proBNP, which has positioned O-304 as a reference standard for researchers exploring ampk biology research outcomes. The compound's selectivity and documented tolerability in preclinical models have contributed to a rapidly growing body of literature over the past decade.
O-304 Documented Benefits: 4 Documented Mechanisms
Pan-AMPK Activation
Activates all AMPK subunit combinations across skeletal muscle, heart, liver, and fat tissue.
Glycemic Control
Reduces HbA1c and fasting glucose in Phase 2 diabetes trials.
Cardiac Benefits
Reduces NT-proBNP (heart failure marker) in diabetic patients with cardiac risk.
Weight Reduction
Produces modest body weight reduction alongside glycemic improvement.
How O-304 Works: Molecular Mechanism & Pathway
Direct allosteric AMPK activator binding the β1 subunit across all AMPK heterotrimers to produce tissue-wide metabolic benefits including glucose uptake, fat oxidation, and cardiac energy efficiency.
The 4 primary research pathways identified for O-304 — Pan-AMPK Activation, Glycemic Control, Cardiac Benefits — collectively point to a compound with pleiotropic activity across interconnected biological systems. Studies have further shown that first pan-AMPK activator in clinical trials, reinforcing the mechanistic picture established in earlier cell-line work. Unlike single-pathway agents, O-304's broad receptor engagement profile continues to generate hypotheses for novel applications beyond its originally characterized use cases.
Research Protocols & Compound Combinations
O-304 is routinely studied alongside MOTS-c and AICAR in metabolic & fat loss-focused compound panels. Researchers investigating ampk biology research have found that pairing compounds with complementary receptor profiles can produce additive results while keeping individual doses within well-characterized ranges. Preliminary evidence that oral bioavailability in capsule form has informed several of these multi-compound protocol designs.
Purity, Testing & Research Grade Standards
All O-304 research material offered through this catalog is manufactured under controlled conditions and independently verified by a third-party laboratory prior to release. Each lot undergoes High-Performance Liquid Chromatography (HPLC) analysis to confirm ≥98% purity, with identity confirmed via mass spectrometry. The accompanying Certificate of Analysis (CoA) documents the exact purity, molecular weight confirmation, and lot-specific testing date — data that should accompany any reproducible research protocol. Lyophilized powder formulation ensures maximum stability during shipping and storage at −20°C long-term or 4°C for short-term use.
◈ Key Highlights
- Phase 2 T2D: reduces HbA1c, body weight, and NT-proBNP
- First pan-AMPK activator in clinical trials
- Oral bioavailability in capsule form
Ideal For
- AMPK biology research
- Diabetes and metabolic research
- Heart failure research
- Exercise mimetic studies
Intended for laboratory use only. Not for human or animal consumption. Not FDA approved. Handle in appropriate lab settings only.
What the Research Shows
The following data points are derived from peer-reviewed preclinical and clinical studies on O-304. All studies cited in compound profiles are indexed in PubMed or published in peer-reviewed journals.
Phase 2 T2D: reduces HbA1c, body weight, and NT-proBNP
First pan-AMPK activator in clinical trials
Oral bioavailability in capsule form
Third-Party Verified Every Batch
Each vial of O-304 is independently tested by a third-party laboratory before fulfillment. You receive the actual CoA (Certificate of Analysis) documentation with your order.
